The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the sales agents in connection with a new SEC-registered at-the-market offering program by Denali Therapeutics Inc. of its common stock for up to an aggregate amount of $400 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “DNLI.”

Based in South San Francisco, California, Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases. Denali Therapeutics pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development with biomarker monitoring to demonstrate target engagement and select patients.

The Davis Polk corporate team included partners Alan F. Denenberg and Yasin Keshvargar and associates Bex Childress and Ashley Jaworoski. The intellectual property team included partner David R. Bauer and associates Adrian Rabin and Emma Willems. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post